Compare PAYO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | RARE |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | 2540 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | N/A | 2013 |
| Metric | PAYO | RARE |
|---|---|---|
| Price | $7.11 | $26.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 20 |
| Target Price | $7.69 | ★ $59.10 |
| AVG Volume (30 Days) | ★ 4.2M | 1.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $7.15 | $13.12 |
| Revenue Next Year | $10.28 | $37.80 |
| P/E Ratio | $30.36 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $4.08 | $18.29 |
| 52 Week High | $7.18 | $39.89 |
| Indicator | PAYO | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 41.64 |
| Support Level | $7.07 | $21.54 |
| Resistance Level | $7.15 | $27.42 |
| Average True Range (ATR) | 0.04 | 1.51 |
| MACD | -0.04 | -0.38 |
| Stochastic Oscillator | 22.22 | 30.07 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.